
What is claimed is:

1. Use of a compound represented by formula (I), or a pharmaceutically acceptable salt thereof or a solvate thereof or a composition containing the compound represented by formula (I), or a pharmaceutically acceptable salt thereof or a solvate thereof in manufacture of a medicament for preventing or treating diseases associated with an increased uric acid level in a mammal,



(I)

wherein R_1 is selected from the group consisting of hydrogen and C_{1-4} alkyl, wherein said C_{1-4} alkyl is unsubstituted or optionally substituted with one or more halogen, cyano, CF_3 or a combination thereof;

R_2 is selected from the group consisting of C_{1-10} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl, wherein said C_{1-10} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl is unsubstituted or optionally substituted with halogen or cyano, or a combination thereof; and

R_3 is selected from the group consisting of halogen and cyano.

2. Use according to claim 1, wherein
R_1 represents hydrogen or methyl,
R_2 represents ethyl, propyl, 2-methylpropyl, butyl, 3-methylbutyl or pentyl, and
R_3 represents fluorine or chlorine.

3. Use according to claim 1, wherein the compound is selected from the group consisting of:

8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione,
8-chloro-3-butyl-3,7-dihydro-1H-purine-2,6-dione,

8-chloro-1-methyl-3-butyl-3,7-dihydro-1H-purine-2,6-dione,
8-chloro-1-methyl-3-pentyl-3,7-dihydro-1H-purine-2,6-dione,
8-chloro-3-(3-methylbutyl)-3,7-dihydro-1H-purine-2,6-dione,
8-chloro-3-(2-methylpropyl)-3,7-dihydro-1H-purine-2,6-dione, and
8-chloro-1-methyl-3-(3-methylbutyl)-3,7-dihydro-1H-purine-2,6-dione.

4. Use according to any one of claims 1 to 3, wherein the compound is 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione, or a hydrate thereof.

5. Use according to any one of claims 1 to 4, wherein the diseases associated with the increased level of uric acid are at least one of a uratic disease and a gouty disease.

6. Use according to claim 5, wherein the uratic disease or the gouty disease is hyperuricemia, gout, gouty inflammation, pain or uric acid nephropathy.

7. Use according to claim 6, wherein the hyperuricemia comprises primary hyperuricemia and secondary hyperuricemia.


8. Use according to claim 6, wherein the gout comprises primary gout and secondary gout.

9. Use according to claim 6, wherein the gouty inflammation is selected from the group consisting of acute gouty arthritis, subcutaneous tophi, and chronic tophi arthritis.

10. Use according to claim 6, wherein the uric acid nephropathy is selected from the group consisting of acute uric acid nephropathy, chronic urate nephropathy and uric acid urolithiasis.

11. Use according to any one of claims 1 to 3, wherein the mammal is human.

12. Use of a compound represented by formula (I), or a pharmaceutically acceptable salt thereof or a solvate thereof, or a composition containing the compound represented by formula (I), or a pharmaceutically acceptable salt thereof or a solvate thereof in manufacture of a medicament for reducing uric acid level in a mammal,



(I)

wherein R_1 is selected from the group consisting of hydrogen and C_{1-4} alkyl, wherein said C_{1-4} alkyl is unsubstituted or optionally substituted with one or more of halogen, cyano, CF_3 or a combination thereof;

R_2 is selected from the group consisting of C_{1-10} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl, wherein said C_{1-10} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl is unsubstituted or optionally substituted with halogen or cyano, or a combination thereof; and

R_3 is selected from the group consisting of halogen and cyano.

13. Use according to claim 12, wherein
R_1 represents hydrogen or methyl,
R_2 represents ethyl, propyl, 2-methylpropyl, butyl, 3-methylbutyl or pentyl, and
R_3 represents fluorine or chlorine.

14. Use according to claim 12, wherein the compound is selected from the group consisting of:

8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione,
8-chloro-3-butyl-3,7-dihydro-1H-purine-2,6-dione,
8-chloro-1-methyl-3-butyl-3,7-dihydro-1H-purine-2,6-dione,

8-chloro-1-methyl-3-pentyl-3,7-dihydro-1H-purine-2,6-dione,
8-chloro-3-(3-methylbutyl)-3,7-dihydro-1H-purine-2,6-dione,
8-chloro-3-(2-methylpropyl)-3,7-dihydro-1H-purine-2,6-dione, and
8-chloro-1-methyl-3-(3-methylbutyl)-3,7-dihydro-1H-purine-2,6-dione.

15. Use according to claim 12, wherein the compound is 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione, or a hydrate thereof.